{
    "Trade/Device Name(s)": [
        "EliA\u2122 Scl-70S",
        "EliA\u2122 Scl-70S Well"
    ],
    "Submitter Information": "Phadia US, Inc.",
    "510(k) Number": "K140493",
    "Predicate Device Reference 510(k) Number(s)": [
        "K924988"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LJM"
    ],
    "Summary Letter Date": "September 24, 2014",
    "Summary Letter Received Date": "September 26, 2014",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.5100"
    ],
    "Regulation Name(s)": [
        "Antinuclear Antibody Immunological Test System"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Scl-70"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Phadia 100",
        "Phadia 250"
    ],
    "Method(s)/Technology(ies)": [
        "Semi-quantitative immunofluorescence assay",
        "Enzyme-labeled immunoassay",
        "Fluorescence detection"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for EliA Scl-70S semi-quantitative immunoassay measuring IgG antibodies to Scl-70 for scleroderma diagnosis using Phadia 100/250 platforms",
    "Indications for Use Summary": "Intended for in vitro semi-quantitative measurement of IgG antibodies directed to Scl-70 in human serum and plasma (heparin, EDTA) as an aid in the clinical diagnosis of scleroderma (diffuse form) in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}